In vitro activity of BAY 12-8039, a new fluoroquinolone, against mycoplasmas

Antimicrobial Agents and Chemotherapy

Volumn 42, Issue 3, 1998, Pages 703-704

  Bebear C M ^a   Renaudin, H ^a   Boudjadja, A ^b   Bebear C ^a  

^a UNIVERSITÉ DE BORDEAUX   (France)

^b Bayer Pharma   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CLARITHROMYCIN; DOXYCYCLINE; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPARFLOXACIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERICIDAL ACTIVITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; MINIMUM INHIBITORY CONCENTRATION; MYCOPLASMA; MYCOPLASMA GENITALIUM; MYCOPLASMA HOMINIS; MYCOPLASMA PNEUMONIAE; NONHUMAN; PRIORITY JOURNAL; UREAPLASMA UREALYTICUM;

EID: 0343935771     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.42.3.703     Document Type: Article

References (9)

1. Aldridge, K. E., and D. Ashcraft. 1997. Comparison of the in vitro activities of BAY 12-8039, a new quinolone, and other antimicrobials against clinically important anaerobes. Antimicrob. Agents Chemother. 41:709-711.
2. Bébéar, C., P. Cantet, H. Renaudin, and C. Quentin. 1985. Activité comparée de la minocycline et doxycycline sur les mycoplasmes pathogénes pour l'homme. Pathol. Biol. 33:577-580.
3. Bebear, C. M., J. M. Bové, C. Bebear, and J. Renaudin. 1997. Characterization of Mycoplasma hominis mutations involved in resistance to fluoroquinolones. Antimicrob. Agents Chemother. 41:269-273.
4. Kaku, M., K. Ishida, K. Irifune, R. Mizukane, H. Takemura, R. Yoshida, H. Tanaka, T. Usui, K. Tomono, N. Suyama, H. Koga, S. Kohno, and K. Hara. 1994. In vitro and in vivo activities of sparfloxacin against Mycoplasma pneumoniae. Antimicrob. Agents Chemother. 38:738-741.
5. Kenny, G. E., and F. D. Cartwright. 1993. Susceptibilities of Mycoplasma hominis, Mycoplasma pneumoniae, and Ureaplasma urealyticum to a new quinolone, OPC 17116. Antimicrob. Agents Chemother. 36:1726-1727.
6. Kenny, G. E., and F. D. Cartwright. 1996. Susceptibilities of Mycoplasma pneumoniae, Mycoplasma hominis, and Ureaplasma urealyticum to a new quinolone, trovafloxacin (CP-99,219). Antimicrob. Agents Chemother. 40:1048-1049.
7. Renaudin, H., and C. Bébéar. 1995. In vitro susceptibility of mycoplasmas to a new quinolone, BAY Y 3118. Drugs 49(Suppl. 2):243-245.
8. Waites, K. B., L. B. Duffy, T. Schmid, D. Crabb, M. S. Pate, and G. H. Cassell. 1991. In vitro susceptibilities of Mycoplasma pneumoniae, Mycoplasma hominis, and Ureaplasma urealyticum to sparfloxacin and PD 127391. Antimicrob. Agents Chemother. 35:1181-1185.
9. Woodcock, J. M., J. M. Andrews, F. J. Boswell, N. P. Brenwald, and R. Wise. 1997. In vitro activity of BAY 12-8039, a new fluoroquinolone. Antimicrob. Agents Chemother. 41:101-106.